Seizure aggravation in idiopathic generalized epilepsies

Epilepsia

Volumn 46, Issue SUPPL. 9, 2005, Pages 133-139

  Chaves, J ^a   Sander, J W ^a   Sander, Ley ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Antiepileptic drugs; Idiopathic generalized epilepsy; Paradoxical intoxication; Paradoxical reaction; Seizure exacerbations

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; GABAERGIC RECEPTOR AFFECTING AGENT; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; POSTSYNAPTIC RECEPTOR; PREGABALIN; SODIUM CHANNEL; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; AMMONIA BLOOD LEVEL; ATONIC SEIZURE; BRAIN DISEASE; BRAIN TOXICITY; COMORBIDITY; COMPLEX PARTIAL SEIZURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; EPILEPTIC STATE; GENERALIZED EPILEPSY; GRAND MAL SEIZURE; HUMAN; HYPERAMMONEMIA; IDIOPATHIC DISEASE; LIVER DYSFUNCTION; MONOTHERAPY; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; PARADOXICAL DRUG REACTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; STUPOR; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; TREATMENT REFUSAL; ACUTE DISEASE; CHEMICALLY INDUCED DISORDER; PRACTICE GUIDELINE;

ACUTE DISEASE; ANTICONVULSANTS; EPILEPSY, GENERALIZED; HUMANS; PATIENT COMPLIANCE; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 32944455269     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.00325.x     Document Type: Review

References (86)

1. Benbadis SR, William O, Tatum WO, et al. Idiopathic generalized epilepsy and choice of antiepileptic drugs. Neurology 2003;61:1793-5.
2. Bauer J. Seizure-inducing effects of antiepileptic drugs: a review. Acta Neurol Scand 1996;94:367-77.
3. Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39:5-17.
4. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998;39(suppl 3):S2-10.
5. Berkovic SF. Aggravation of generalized epilepsies. Epilepsia 1998;39(suppl 3):S11-4.
6. Genton P, McMenamin J. Aggravation of seizures by antiepileptic drugs: what to do in clinical practice. Epilepsia 1998;39(suppl 3):S26-9.
7. Genton P. When antiepileptic drugs aggravate epilepsy? Brain Dev 2000;22:75-80.
8. Hirsch E, Genton P. Antiepileptic drug-induced pharmacodynamic aggravation of seizures. Does valproate have a lower potential? CNS Drugs 2003;17:633-40.
9. Bourgeois BFD. Chronic management of seizures in the syndromes of idiopathic generalized epilepsy. Epilepsia 2003;44(suppl 2):27-32.
10. Yamamoto M. The causes of acute intoxication by anticonvulsants. Epilepsia 1999;40(suppl 2):287.
11. Troupin AS, Ojemann LM. Paradoxical intoxication - a complication of anticonvulsant administration. Epilepsia 1975;16:753-8.
12. Deckers CL, Genton P, Sills GJ, et al. Current limitations of antiepileptic therapy. Epilepsy Res 2003;53:1-17.
13. Bittencourt PR, Richens A. Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia 1981;22:129-34.
14. Tassinari CA, Dravet C, Roger J, et al. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia 1972;13:421-35.
15. Papini M, Pasquinelli A, Armellini M, et al. Alertness and incidence of seizures in patients with Lennox-Gastaut syndrome. Epilepsia 1984;25:161-7.
16. Ehrenberg B. Importance of sleep restoration in co-morbid disease: effect of anticonvulsants. Neurology 2000;54(suppl 1):S33-7.
17. Kohrman MH, Reddick D. Increased symptoms of excessive day-time sleepiness in children with epilepsy. Epilepsia 2002;43(suppl 7):42.
18. Somerville ER. Aggravation of partial seizures by antiepileptic drugs. Is there evidence from clinical trials? Neurology 2002;59:79-83.
19. Macdonald RL, Kelly KM.Antiepileptic drug mechanisms of action. Epilepsia 1993;34(suppl 5):S1-8.
20. Snead OC, Hosey LC. Exacerbation of seizures in children by carbamazepine. New Engl J Med 1985;313:916-21.
21. Gansauer M, Alsaadi TM. Carbamazepine-induced seizures: a case report and review of the literature. Clin Electroencephalogr 2002;33:174-7.
22. Elson L, Ruggles KH, Cascino GD, et al. Seizure exacerbation and status epilepticus related to carbamazepine-10,11-epoxide. Ann Neurol 1994;35:743-5.
23. Prasad AN, Stefanelli M, Nagarajan L. Seizure exacerbation and developmental regression with carbamazepine. Can J Neurol Sci 1998;25:287-94.
24. Yang MT, Lee WT, Chu LW, et al. Anti-epileptic drugs-induced de novo absence seizures. Brain Dev 2003;25:51-6.
25. Sampaio LP, Valente KD, Manreza ML, et al. New seizures types and EEG patterns after introduction of oxcarbamazepine or carbamazepine. Epilepsia 2000;41(suppl 7):190.
26. Sachdeo R, Chokroberty S. Enhancement of absence with Tegretol. Epilepsia 1985;26:1985.
27. Parker APJ, Agothonikou A, Robinson RO, et al. Inappropriate use of carbamazepine in children with typical absence seizures. Epilepsia 1997;38(suppl 3):98.
28. Osorio I, Reed RC, Peltzer JN. Refractory idiopathic absence status epilepticus: a probable paradoxical effect of phenytoin and carbamazepine. Epilepsia 2001;41:887-94.
29. Liporace JD, Sperling MR, Dichter MA. Absence seizures and carbamazepine in adults. Epilepsia 1994;35:1026-8.
30. Parmeggiani A, Fraticcelli E, Rossi PG. Exacerbation of epileptic seizures by carbamazepine: report of 10 cases. Seizure 1998;7:479-83.
31. Shields WD, Saslow E. Myoclonic, atonic and absence seizures following institution of carbamazepine therapy in children. Neurology 1983;33:1487-9.
32. Talwar D, Arora MS, Sher PK. EEG changes and seizure exacerbation in young children treated with carbamazepine. Epilepsia 1994;35:1154-9.
33. Kochen S, Giagante B, Oddo S. Spike-and-wave complexes and seizure exacerbation caused by carbamazepine. Eur J Neurol 2002;9:41-7.
34. Parker AP, Agathonikou A, Robinson RO, et al. Inappropriate use of carbamazepine and vigabatrin in typical absence seizures. Dev Med Child Neurol 1998;40:517-9.
35. Osorio I, Peltzer J, Reed R. Carbamazepine and phenytoin exacerbate primary generalized epilepsy. Epilepsia 1996;37(suppl 5):93.
36. Genton P, Gelisse P, Thomas P, et al. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-9.
37. Weaver DF, Camfield P, Fraser A. Massive carbamazepine overdose: clinical and pharmacologic observations in five episodes. Neurology 1988;38:755-9.
38. Spiller HA, Carlisle RD. Status epilepticus after massive carbamazepine overdose. J Toxicol Clin Toxicol 2002;40:81-90.
39. Monji A, Maekawa T, Yanagimoto K, et al. Carbamazepine may trigger new-onset epileptic seizures in an individual with autism spectrum disorders: a case report. Eur Psychiatry 2003;19:322-3.
40. Cocito L, Audenino D, Primavera A. Antiepileptic drugs may trigger absence status epilepticus. Epilepsia 1998;39:89.
41. Roseman E. Dilantin toxicity: A clinical and electroencephalographic study. Neurology 1961;11:912-21.
42. Eldridge R, Iivanainen M, Stern R, et al. "Baltic" myoclonus epilepsy: hereditary disorder of childhood madeworse by phenytoin. Lancet 1983;8:838-42.
43. Pellock JM. Treatment considerations: traditional antiepileptic drugs. Epilepsy Behav 2002;3:S18-23.
44. Hamano SI, Mochizuki M, Morikawa T. Phenobarbital-induced atypical absence seizure in benign childhood epilepsy with centrotemporal spikes. Seizure 2002;11:201-4.
45. Lerman-Sagie T, Watenberg N; Kramer U, et al. Absence seizures aggravated by valproic acid. Epilepsia 2001;42:941-3.
46. Capocchi G, Balducci A, Cecconi M, et al. Valproate-induced epileptic tonic status. Seizure 1998;7:237-41.
47. Zaccara G, Paganini M, Campostrini R, et al. Hyperammonemia and valproate-induced alterations of the state of consciousness: a report of 8 cases. Eur Neurol 1984;23:104-12.
48. Zaret BS, Beckner RR, Marini AM, et al. Sodium valproate induced hyperammonemia without clinical hepatic dysfunction. Neurology 1982;32:206-8.
49. Chadwick DW, Cumming WJK, Livingstone I, et al. Acute intoxication with sodium valproate. Ann Neurol 1979;6:552-3.
50. Meyer A, Fröscher W. Recurrent confusional states associated with absence status and valproate-associated encephalopathy. Epilepsy 1997;38:389.
51. Shahar E, Andraus J, Sagie-Lerman T, et al. Valproic acid therapy inducing absence status evolving into generalized seizures. Pediatr Neurol 2002;26:402-4.
52. Aguglia U, Gambardella A, Zappia M, et al. Negative myoclonus during valproate-related stupor. Neurophysiological evidence of a cortical non-epileptic origin. Electroencephalogr Clin Neurophysiol 1995;94:103-8.
53. Haas AML, Kuilman M. Ethosuximide (α-ethyl-α- methylsuccinimide) and grand mal. Epilepsia 1964;5:90-6.
54. Todorov AB, Lenn NJ, Gabor AJ. Exacerbation of generalized nonconvulsive seizures with ethosuximide therapy. Arch Neurol 1978;35:389-91.
55. Mandelbaum DE, Kugler SL, Wollack JB, et al. Apparent induction of exacerbation of primary generalized seizures after initiation of oxcarbazepine. Epilepsia 2002;43(suppl 7):208.
56. Nielson JB, Uldall P, Bucholt J. Exacerbation of seizures by oxcarbazepine and vigabatrin in children. Epilepsia 1997;38(suppl 3):27.
57. Gaily E, Granström, Liukkonen E. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. J Intellect Disabil Res 1998;42(suppl 1):41-5.
58. Lortie A, Chiron C, Mumford J, et al. The potential for increasing seizure frequency, relapse, and appearance of newseizure types with vigabatrin. Neurology 1993;43(suppl 5):S24-7.
59. Krom MCTFM, Verduin N, Visser E, et al. Status epilepticus during vigabatrin treatment: a report of three cases. Seizure 1995;4:159-62.
60. Sharief MK, Sander JW, Shorvon SD. Acute encephalopathy with vigabatrin. Lancet 1993;342:619.
61. Knake S, Hamer HM, Schomburg U, et al. Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure 1999;8:314-7.
62. Skardoutsou A, Voudris KA, Vagiakou EA. Non-convulsive status epilepticus associated with tiagabine therapy in children. Seizure 2003;12:599-601.
63. Zhu Yu, Vaughn BV. Nonconvulsive status epilepticus induced by tiagabine in a patient with pseudoseizure. Seizure 2002;11:57-9.
64. Biraben A, Allain H, Scarabin JM, et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000;55:1758.
65. Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508-12.
66. Martinez JF, Fountain NB. Frequency of myoclonic seizure exacerbation by lamotrigine in JME. Epilepsia 2003;44(suppl 9):268.
67. Stein AG, Carrazana EJ. The use of lamotrigine in juvenile myoclonic epilepsy. Epilepsia 2001;42(suppl 7):261.
68. Janzky J, Rásonyi G, Halász P, et al. Disabling erratic myoclonus during lamotrigine therapy with high serum level-report of two cases. Clin Neuropharmacol 2000;23:86-9.
69. Guerrini R, Belmonte A, Parmeggiani L, et al. Myoclonic status epilepticus following high-dosage lamotrigine therapy. Brain Dev 1999;21:420-4.
70. Rogers SJ, Szabo CA, Hartig JL, et al. Topiramate in the treatment of primary generalized epilepsy. Epilepsia 1999;40(suppl 7):219.
71. Asconapé J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia 2000;41:479-81.
72. Vossler DG. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin. Neurology 1996;46:852-3.
73. Dixit SN, Maganti RK, Lotz BP, et al. Gabapentin-induced status epilepticus. Epilepsia 2002;43(suppl 7):204-5.
74. Asconape JJ, Hartman LM, Salanova V, et al. Pregabaline-associated myoclonus. Epilepsia 1999;40(suppl 7):143.
75. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001;42:790-2.
76. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004; 101:9861-6.
77. Depondt C, Yuen AW, Bell G, et al. The long-term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry 2005; (in press).
78. Nakken KO, Eriksson AS, Lossius R, et al. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. Seizure 2003;12:42-6.
79. Karceski SC, Bazil C, Pack A.Worsening of seizures with levetiracetam. Epilepsia 2002;43(suppl 7):293.
80. Montouris GD, Lippmann SM, Rosenfeld WE. Exacerbation of seizures: any relationship to dose escalation of levetiracetam? Epilepsia 2001;42(suppl 7):184.
81. Goldstein JL. Levetiracetam: exacerbation of epilepsy. Epilepsia 2001;42(suppl 7):254-5.
82. Sztankrycer MD, Huang EE, Bond GR. Acute zonisamide overdose: a death revisited. Vet Hum Toxicol 2003;45:154-6.
83. Alvarez N, Hartford E. Epileptic seizures induced by clonazepam. Clin Electroencephalogr 1981;12:57-65.
84. Tassinari CA, Dravet C, Roger J, et al. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia 1972;13:421-35.
85. DiMario FJJ, Clancy RR. Paradoxical precipitation of tonic seizures by lorazepam in child with atypical absence seizures. Pediatr Neurol 1998;4:249-51.
86. Nabbout R, Dulac O. Epileptic encephalopathies: a brief overview. J Clin Neurophysiol 2003;20:393-7.